Angelika Joos,
MPharm
Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc.
Angelika Joos has been responsible for Regulatory Policy issues within MSD's Global Regulatory Affairs and Clinical Safety department since 2001 and currently heads the EU office in Brussels. In her current position as Executive Director, Global Regulatory Policy, she oversees activities in Europe, Middle East, Africa and Asia-Pacific. Her role includes identifying regulatory policy priorities that align with MSD’s business priorities and leading cross-functional expert networks to define policy positions. She also informs the company’s regulatory strategy development by providing perspectives on the external environment evolution into MSD’s regulatory affairs community.
Ms. Joos has gained strategic as well as operational experience with European regulatory procedures and with various products in different therapeutic areas over the past two decades. She has more than 15 years of experience of working with various trade associations and professional organizations at the EU and international levels. She represents MSD in various Committees of EFPIA, EuropaBio and EUCOPE, and is actively involved in international policy activities as MSD delegate in the IFPMA Regulatory & Technical Policy Committee.
Ms. Joos has been a DIA Board member since 2014. She served as Chair of the DIA Advisory Council Europe from 2008-2015. She received the DIA Outstanding Service Award in 2013 and was Co-Chair of the DIA 2014 EuroMeeting in Vienna. She is a pharmacist by training and her main interests are related to regulatory frameworks, clinical trials environment, RA/HTA interface, pediatric development and patient involvement.
Our Leadership
-
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
MS • Global Chief Executive
DIA
-
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
MD •Director DIA
Chief Scientific Officer
Syneos Health -
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
PhD •Director DIA
Senior Vice President
QIAGEN -
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
PharmD • Chair, Executive Committee
-
CPA • Member, Executive Committee -
MBA • Member, Executive Committee -
RPh • Member, Executive Committee -
MS • Member, Executive Committee
-
CPA • Chair, Audit Committee -
MD, PhD, DSc • Member, Audit Committee -
MPharm • Member, Audit Committee -
PharmD • Member, Audit Committee -
PharmD • Member, Audit Committee
-
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
MS • Global Chief Executive -
MS, CPA • Chief Financial Officer -
-
DIA EMEA -
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
PhD • Senior Vice President & Managing Director
DIA Americas -
PhD • Senior Vice President & Managing Director
DIA Japan -
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China